Explore

Trendline Trendline
Novocure Reports 12% Revenue Growth in Q1 2026 Driven by Global Expansion

Novocure Reports 12% Revenue Growth in Q1 2026 Driven by Global Expansion

Novocure Reports 12% Revenue Growth in Q1 2026 Driven by Global Expansion
Trendline Trendline
Novocure Reports Strong Q1 2026 Financial Results with Growth in Optune Gio Therapy

Novocure Reports Strong Q1 2026 Financial Results with Growth in Optune Gio Therapy

Novocure Reports Strong Q1 2026 Financial Results with Growth in Optune Gio Therapy
Trendline Trendline
Bicycle Therapeutics Reports Q1 2026 Financial Results, Highlights Progress in Cancer Therapies

Bicycle Therapeutics Reports Q1 2026 Financial Results, Highlights Progress in Cancer Therapies

Bicycle Therapeutics Reports Q1 2026 Financial Results, Highlights Progress in Cancer Therapies
Trendline Trendline
Merck Discontinues Early-Stage TROP ADC Amid Strategic Shifts in Oncology

Merck Discontinues Early-Stage TROP ADC Amid Strategic Shifts in Oncology

Merck Discontinues Early-Stage TROP ADC Amid Strategic Shifts in Oncology
Trendline Trendline
Amylyx Pharmaceuticals to Announce Q1 2026 Financial Results Amid Strategic Focus on Neurodegenerative Diseases

Amylyx Pharmaceuticals to Announce Q1 2026 Financial Results Amid Strategic Focus on Neurodegenerative Diseases

Amylyx Pharmaceuticals to Announce Q1 2026 Financial Results Amid Strategic Focus on Neurodegenerative Diseases
Trendline Trendline
Eli Lilly's Foundayo Weight Loss Pill Sees Strong Initial Demand with Over 20,000 Users

Eli Lilly's Foundayo Weight Loss Pill Sees Strong Initial Demand with Over 20,000 Users

Eli Lilly's Foundayo Weight Loss Pill Sees Strong Initial Demand with Over 20,000 Users
Trendline Trendline
Prolong Pharmaceuticals' Stroke Therapy PP-007 Gains FDA Breakthrough Designation

Prolong Pharmaceuticals' Stroke Therapy PP-007 Gains FDA Breakthrough Designation

Prolong Pharmaceuticals' Stroke Therapy PP-007 Gains FDA Breakthrough Designation
Trendline Trendline
Merck Reports Strong Q1 Results Driven by Keytruda Sales, Adjusts 2026 Outlook

Merck Reports Strong Q1 Results Driven by Keytruda Sales, Adjusts 2026 Outlook

Merck Reports Strong Q1 Results Driven by Keytruda Sales, Adjusts 2026 Outlook
Trendline Trendline
NutriBand Reports $2.04M Revenue and $8.23M Net Loss for Fiscal Year 2026

NutriBand Reports $2.04M Revenue and $8.23M Net Loss for Fiscal Year 2026

NutriBand Reports $2.04M Revenue and $8.23M Net Loss for Fiscal Year 2026
Trendline Trendline
AbbVie Secures Option to Acquire Kestrel Therapeutics for $1.45 Billion in KRAS Inhibitor Deal

AbbVie Secures Option to Acquire Kestrel Therapeutics for $1.45 Billion in KRAS Inhibitor Deal

AbbVie Secures Option to Acquire Kestrel Therapeutics for $1.45 Billion in KRAS Inhibitor Deal
Trendline Trendline
Soligenix Halts Phase 3 Trial of HyBryte for Cutaneous T-Cell Lymphoma Due to Futility

Soligenix Halts Phase 3 Trial of HyBryte for Cutaneous T-Cell Lymphoma Due to Futility

Soligenix Halts Phase 3 Trial of HyBryte for Cutaneous T-Cell Lymphoma Due to Futility
Trendline Trendline
FDA Approves Taiho Oncology's ADC ARC-02 for Phase 1 Clinical Trials in Non-Hodgkin Lymphoma

FDA Approves Taiho Oncology's ADC ARC-02 for Phase 1 Clinical Trials in Non-Hodgkin Lymphoma

FDA Approves Taiho Oncology's ADC ARC-02 for Phase 1 Clinical Trials in Non-Hodgkin Lymphoma